End-of-day quote
Korea S.E.
23:00:00 30/05/2024 BST
|
5-day change
|
1st Jan Change
|
2,105
KRW
|
-0.24%
|
|
+1.94%
|
-37.72%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
631,931
|
491,644
|
566,198
|
345,966
|
244,105
|
124,245
|
Enterprise Value (EV)
1 |
574,284
|
460,341
|
522,763
|
298,494
|
184,866
|
91,085
|
P/E ratio
|
-43
x
|
-28.6
x
|
-19.5
x
|
-11.7
x
|
-5.84
x
|
-4.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,572
x
|
1,202
x
|
278
x
|
4,704
x
|
1,132
x
|
944
x
|
EV / Revenue
|
1,428
x
|
1,126
x
|
257
x
|
4,059
x
|
857
x
|
692
x
|
EV / EBITDA
|
-46.8
x
|
-28.1
x
|
-23.1
x
|
-9.85
x
|
-5.63
x
|
-3.51
x
|
EV / FCF
|
-66.2
x
|
-20
x
|
260
x
|
-9.95
x
|
-5.81
x
|
-5.87
x
|
FCF Yield
|
-1.51%
|
-5%
|
0.38%
|
-10.1%
|
-17.2%
|
-17%
|
Price to Book
|
8.15
x
|
7.83
x
|
9.73
x
|
5.11
x
|
2.78
x
|
2.06
x
|
Nbr of stocks (in thousands)
|
21,791
|
21,916
|
22,588
|
23,219
|
36,763
|
36,759
|
Reference price
2 |
29,000
|
22,433
|
25,067
|
14,900
|
6,640
|
3,380
|
Announcement Date
|
28/03/19
|
19/03/20
|
23/03/21
|
23/03/22
|
15/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
402
|
408.9
|
2,036
|
73.54
|
215.7
|
131.7
|
EBITDA
1 |
-12,263
|
-16,397
|
-22,591
|
-30,297
|
-32,815
|
-25,959
|
EBIT
1 |
-13,728
|
-18,335
|
-24,888
|
-33,560
|
-36,733
|
-29,784
|
Operating Margin
|
-3,414.59%
|
-4,484.32%
|
-1,222.23%
|
-45,632.96%
|
-17,032.78%
|
-22,622.84%
|
Earnings before Tax (EBT)
1 |
-13,233
|
-17,131
|
-28,768
|
-29,575
|
-34,470
|
-28,342
|
Net income
1 |
-13,233
|
-17,131
|
-28,768
|
-29,257
|
-33,427
|
-27,718
|
Net margin
|
-3,291.6%
|
-4,189.82%
|
-1,412.78%
|
-39,782.05%
|
-15,499.53%
|
-21,054.04%
|
EPS
2 |
-673.9
|
-783.7
|
-1,286
|
-1,273
|
-1,137
|
-754.1
|
Free Cash Flow
1 |
-8,680
|
-23,028
|
2,009
|
-30,011
|
-31,797
|
-15,506
|
FCF margin
|
-2,159.04%
|
-5,631.96%
|
98.67%
|
-40,807.94%
|
-14,744.09%
|
-11,777.71%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
19/03/20
|
23/03/21
|
23/03/22
|
15/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
57,647
|
31,303
|
43,435
|
47,473
|
59,240
|
33,160
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-8,680
|
-23,028
|
2,009
|
-30,011
|
-31,797
|
-15,506
|
ROE (net income / shareholders' equity)
|
-20.6%
|
-24.4%
|
-47.4%
|
-45.3%
|
-42.3%
|
-36.8%
|
ROA (Net income/ Total Assets)
|
-12%
|
-14.2%
|
-17.1%
|
-19.1%
|
-21%
|
-21%
|
Assets
1 |
110,705
|
120,397
|
167,880
|
152,891
|
158,808
|
131,905
|
Book Value Per Share
2 |
3,556
|
2,867
|
2,576
|
2,916
|
2,386
|
1,644
|
Cash Flow per Share
2 |
1,551
|
310.0
|
1,359
|
1,303
|
1,083
|
825.0
|
Capex
1 |
3,037
|
13,115
|
5,657
|
5,048
|
1,826
|
100
|
Capex / Sales
|
755.4%
|
3,207.62%
|
277.79%
|
6,863.53%
|
846.87%
|
76.28%
|
Announcement Date
|
28/03/19
|
19/03/20
|
23/03/21
|
23/03/22
|
15/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -37.72% | 56.01M | | -1.85% | 89.87B | | -3.95% | 37.57B | | +61.79% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +4.04% | 9.11B | | -19.65% | 7.32B |
Biopharmaceuticals
|